Breast Cancer Screening Test Global Market Report 2025

The increasing incidence of breast cancer is anticipated to drive the growth of the breast cancer screening test market. Breast cancer involves the abnormal and uncontrolled growth of cells in breast tissue, which can develop into a tumor and potentially spread to other body parts. The rise in breast cancer cases is attributed to the aging global population, as older age significantly raises the risk of developing the disease, and longer life expectancies mean a greater number of individuals are at risk. Screening tests for breast cancer are essential for identifying the disease in its early stages, thereby improving treatment outcomes and lowering mortality rates. For example, in March 2025, Breastcancer.org, a nonprofit organization based in the US, projected that approximately 316,950 women would be diagnosed with invasive breast cancer in 2025, along with 59,080 new cases of non-invasive ductal carcinoma in situ (DCIS). Additionally, in December 2024, the Public Health Agency of Canada reported that an estimated 28,600 women in Canada were expected to be diagnosed with breast cancer in 2022, with 5,500 fatalities anticipated. As a result, the rising prevalence of breast cancer is contributing to the expansion of the breast cancer screening test market.

Leading companies in the breast cancer screening test sector are prioritizing the development of cutting-edge solutions such as mobile screening units to improve accessibility, increase early detection, and extend services to underserved or remote regions. These mobile units are transportable facilities equipped with diagnostic imaging technologies like mammography, designed to deliver on-site breast cancer screening in areas lacking adequate healthcare access. For instance, in September 2024, Granules India Ltd., a pharmaceutical company based in India, introduced the Breast Health Express to promote breast cancer screening in disadvantaged communities. Outfitted with advanced mammography and ultrasound systems, the unit facilitates quality screenings while on the move. This initiative aims to bring early detection services to rural and underserved areas, helping to ensure access to critical healthcare for women in these regions.

In August 2024, Hitachi High-Tech Corporation, a Japan-based producer of electronic and electrical equipment, entered into a strategic alliance with Gencurix Inc. for an undisclosed amount. Through this collaboration, Hitachi seeks to utilize its knowledge in in vitro diagnostics and digital technologies to create accurate and efficient molecular diagnostics for cancer. Gencurix Inc., headquartered in South Korea, specializes in breast cancer testing solutions.

Major players in the breast cancer screening test market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH, Fujifilm Corporation, Koninklijke Philips NV, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Hologic Inc., Hitachi High-Tech Corporation, Exact Sciences Corporation, Natera Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, Provista Diagnostics Inc., POC Medical Systems Inc., Niramai Health Analytix Pvt. Ltd., Kheiron Medical Technologies Limited, UE LifeSciences Inc., Dxcover Limited.

North America was the largest region in the breast cancer screening test market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in breast cancer screening test report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the breast cancer screening test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The breast cancer screening test market consists of revenues earned by entities by providing services such as early detection, risk assessment, and tumor detection. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast cancer screening test market also consists of sales of products including ultrasound equipment, screening software, and breast self-examination kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

A breast cancer screening test is a medical procedure or diagnostic method designed to detect breast cancer at an early stage, often before any symptoms develop. The main objective of screening is to discover cancer when it is most treatable, thereby potentially lowering mortality rates and enhancing patient outcomes. Early diagnosis through breast cancer screening enables timely treatment and leads to a more favorable prognosis.

The primary types of diagnostic tests used in breast cancer screening include blood marker tests, imaging tests, genetic tests, and immunohistochemistry tests. Blood marker tests identify and quantify specific substances in the blood to support disease detection, monitoring, or risk evaluation. Different levels of risk - high-risk, moderate-risk, and average-risk populations - are considered, and the tests are utilized by various end users, including hospitals, diagnostic centers, cancer institutes, and research laboratories.

The breast cancer screening tests market research report is one of a series of new reports that provides breast cancer screening tests market statistics, including the breast cancer screening tests industry's global market size, regional shares, competitors with the breast cancer screening tests market share, detailed breast cancer screening tests market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer screening tests market. This breast cancer screening tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The breast cancer screening test market size has grown strongly in recent years. It will grow from $2.31 billion in 2024 to $2.51 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth during the historic period can be credited to enhanced reimbursement policies, a stronger emphasis on preventive healthcare, increased health awareness, greater investment in research and development, and heightened awareness regarding early detection.

The breast cancer screening test market size is expected to see strong growth in the next few years. It will grow to $3.46 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The anticipated growth in the forecast period can be linked to the rising incidence of breast cancer, increased government initiatives, growing healthcare spending, the expansion of mobile screening units, and a rise in the female population. Key trends expected during this period include technological advancements in imaging, the emergence of non-invasive screening techniques, progress in genetic testing, innovations in genomic testing, and the development of mobile screening solutions.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.